Birchview Capital’s Pacific Biosciences PACB Stock Holding History

Birchview Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.98M	Buy	1,500,000 +1,000,000	+200%	+$1.79M	1.13%	26
2025 Q4	$935K	Hold	500,000	–	–	0.55%	41
2025 Q3	$640K	Buy	500,000 +100,000	+25%	+$135K	0.48%	46
2025 Q2	$496K	Buy	+400,000	New	+$462K	0.49%	44
2017 Q3	–	Sell	-27,000	Closed	-$96K	–	42
2017 Q2	$96K	Hold	27,000	–	–	0.05%	38
2017 Q1	$140K	Hold	27,000	–	–	0.08%	39
2016 Q4	$103K	Hold	27,000	–	–	0.06%	41
2016 Q3	$242K	Hold	27,000	–	–	0.14%	33
2016 Q2	$190K	Hold	27,000	–	–	0.14%	34
2016 Q1	$230K	Buy	+27,000	New	+$266K	0.16%	33

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Birchview Capital's PACB Position: Q1 2026 in Review

Birchview Capital increased its Pacific Biosciences (PACB) stake by 200% in Q1 2026, buying an estimated $1.79M and bringing the position to 1,500,000 shares worth $1.98M. The position accounts for 1.13% of the portfolio, ranked #26.

Birchview Capital first reported a position in PACB in Q1 2016 and has held it in 10 quarters since. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Birchview Capital held 1,500,000 shares of Pacific Biosciences worth $1.98M as of Q1 2026.
Birchview Capital bought 1,000,000 Pacific Biosciences shares in Q1 2026, an estimated $1.79M.
Pacific Biosciences made up 1.13% of Birchview Capital's portfolio in Q1 2026, its #26 holding.
Birchview Capital first reported a position in Pacific Biosciences in Q1 2016 and has held it in 10 quarters since.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.